Celebrating the 43rd anniversary of @CNN So proud to be among these talented and dedicated journalists, past and present. – at Atlanta, GA

The flu is back. Bright pink line was last season. Red triangles this year. In the latest data, we have crossed the national baseline, meaning flu activity is officially elevated in the U.S.

CDC has been monitoring school closures by using Google News alerts. To date, there have been more than 2,000 COVID-19 related school closures nationwide affecting more than 1 million children and 68,000 teachers. The states with the most closures are darkest on map. #VRBPAC

Sorry I didn't have this handy when I replied, but here's data presented from an analysis of VSD data by CDC. Overall risk is still low, but clear difference between vaccines.

In a safety update, FDA says J&J shots appear to be linked to rare, but serious adverse blood clotting problems. These events are under review.

J&J is presenting new data - just published this morning in the NEJM, comparing the immune responses of the 3 authorized vaccines in the U.S.

The FDA's #VRBPAC is being asked to consider some of the messiest and most confusing voting questions I've ever seen for the J&J booster dose.

Moderna's booster study didn't meet the second FDA-set bar for effectiveness, probably because the first two doses were still so effective--so it was really hard to get a 4-fold rise in antibodies when they were already so high to begin with. #VRBPAC

Moderna is now presenting data showing that breakthrough COVID-19 infections increased by 36% in the earliest vaccinated participants in its original study compared to those in the placebo group, who were unblinded and vaccinated later. #VRBPAC

It's complicated modeling, but it highlights the role of the vaccines (and boosters) in preventing transmission. Makes a strong case for maintaining high levels of antibodies in healthcare workers, for their protection and their patients.

Third doses boost levels of binding and neutralizing antibodies. But antibodies are are only part of the picture. Emerging research suggests they may account for about 68% of vaccine efficacy against symptomatic infection.